Pfizer Inc. $PFE Shares Purchased by Perpetual Ltd

Perpetual Ltd grew its stake in Pfizer Inc. (NYSE:PFE) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 130,052 shares of the biopharmaceutical company’s stock after buying an additional 18,660 shares during the period. Perpetual Ltd’s holdings in Pfizer were worth $3,238,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. United Bank raised its stake in shares of Pfizer by 12.4% in the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Capital Advisors Wealth Management LLC lifted its holdings in shares of Pfizer by 8.2% during the second quarter. Capital Advisors Wealth Management LLC now owns 9,941 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 752 shares during the period. Finally, Cresset Asset Management LLC boosted its position in Pfizer by 49.6% in the second quarter. Cresset Asset Management LLC now owns 709,582 shares of the biopharmaceutical company’s stock valued at $17,200,000 after buying an additional 235,163 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $28.37 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The stock has a market capitalization of $161.29 billion, a price-to-earnings ratio of 20.86 and a beta of 0.43. The firm’s 50 day simple moving average is $27.09 and its 200-day simple moving average is $25.83. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS. Analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on PFE. Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Morgan Stanley set a $27.00 price objective on shares of Pfizer and gave the stock a “positive” rating in a research note on Tuesday, March 17th. Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, February 4th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, UBS Group started coverage on Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.